Skip to main content

MDXG

Stock
Health Care
Biotechnology

Performance overview

MDXG Price
Price Chart

Forward-looking statistics

Beta
0.81
Risk
48.94%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Company info

SectorHealth Care
IndustryBiotechnology
Employees879
Market cap$1.0B

Fundamentals

Enterprise value$814.7M
Revenue$352.4M
Revenue per employee
Profit margin11.40%
Debt to equity9.20

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.27
Dividend per share
Revenue per share$2.39
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$5M
Put-call ratio

Macro factor sensitivity

Growth+0.8
Credit+4.3
Liquidity-1.6
Inflation-0.9
Commodities+1.0
Interest Rates-3.2

Valuation

Dividend yield0.00%
PEG Ratio20.45
Price to sales2.66
P/E Ratio20.45
Enterprise Value to Revenue2.31
Price to book4.61

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research (July 9, 2025)
Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials

MiMedx Group Inc (NASDAQ: MDXG) stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion Membrane (mdHACM). Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B trial for Knee Osteoarthritis (KOA) did not meet primary endpoints.

Benzinga (September 13, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free